Business
Earth Science Tech, Inc. Launches Earth Science Pharmaceutical & MSN-2 Medical Device Websites, Adds Michel Gauthier M.D. to the Advisory Board, and Reports Over 80% Profit Increase
Earth Science Tech, Inc. Launches Earth Science Pharmaceutical & MSN-2 Medical Device Websites, Adds Michel Gauthier M.D. to the Advisory Board, and Reports Over 80% Profit Increase.
About this update from Earth Science Tech, Inc.
[{"type":"text","content":"\n\n Hollywood, June 19, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTCPINK: ETST), an innovative biotech company focused on cannabis CBD-based (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, medical devices launches a new pharmaceutical & MSN-2 medical device websites to keep stakeholders updated with new developments, progress, and material events in addition to reporting profit increases of over 80% through the year end of 2016.\n ETST is pleased to share that it has finalized and launched the new Earth Science Pharma and MSN-2 Medical Device websites, in order to provide stakeholders with continuous updates on the MSN-2 development and providing educational material on its powerful benefits, which were briefly discussed in the end of March. To accelerate the closing of the pre-launch process of the MSN-2 medical device, ETST has added Michel Gauthier, M.D. to the advisory board. Dr. Gauthier is a real globe trotter, and will become the medical science liaison for the company’s MSN-2 medical device around the globe. As a medical doctor, he has the ability to prescribe the diagnostic test for the women testing the device, which is mandatory in Canada and the vast majority of states in the USA. He will be able to spread the news of Earth Science Tech’s hard work to prevent sexually transmitted infections (STIs) all around the world. Dr. Michel Aube, ETST’s CEO and CSO shares, “We are very excited to be completing the pre-launch groundwork that will allow us to offer to women a more private and self-directed technique to get tested for STIs. This product, along with the associated diagnostic tests that will be done in our dedicated laboratories, will be beneficial for all sexually active women aged between 15 and 25 years old. This represents 500 million young women around the world. The biological sample collected by our first medical device is so stable that the product can be used by women far from urban areas without worry for the preservation of the specimen under different temperature conditions. I anticipate a great future for this innovative tool.” The MSN-2 website will help to introduce the product in different countries while the company builds a brand that will be attractive for young women, their parents and other consumers...